A carbonyl reductase catalytic system and its application

By modifying the carbonyl reductase and coenzyme regeneration system and combining organic/aqueous two-phase catalysis, the problems of insufficient enzyme catalytic stability and conversion efficiency under industrial-grade low-purity ECAA were solved, achieving efficient R-CHBE production and reducing production costs.

CN123107944APending Publication Date: 2026-11-17ANHUI MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611486579.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-23
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies, under industrial-grade low-purity ECAA conditions, suffer from insufficient enzyme catalytic stability and conversion efficiency, resulting in high production costs and significant impact from non-target components, with a lack of targeted solutions.

Method used

By modifying the amino acid sequence of carbonyl reductase, one or more reductase variants are developed. Combined with a coenzyme regeneration system and an organic/aqueous two-phase catalytic system, the catalytic environment of industrial-grade low-purity ECAA is optimized to achieve stable catalysis at high concentrations.

Benefits of technology

Under high concentrations of industrial-grade ECAA, it maintains high catalytic stability and conversion efficiency, reduces dependence on high-purity ECAA feedstock, and improves the industrial applicability of the R-CHBE biomanufacturing process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123107944A_ABST
    Figure CN123107944A_ABST
Patent Text Reader

Abstract

This invention relates to the fields of biocatalysis and industrial biotechnology, providing a carbonyl reductase catalytic system and its applications. Addressing the problem of insufficient enzyme stability at high substrate concentrations due to non-target components in low-purity industrial-grade ECAA, this invention provides a carbonyl reductase and its variants with the amino acid sequence shown in SEQ ID NO.1, or reductase variants obtained by substituting, deleting, inserting, or adding one or more amino acids to the amino acid sequence shown in SEQ ID NO.1. This reductase is then combined with a coenzyme regenerator and an organic / aqueous two-phase system for the asymmetric reduction of ECAA. Using industrial-grade ECAA with a purity of approximately 95%, and reacting at a substrate concentration of 100–120 g / L for no more than 10 h, the ECAA conversion rate is greater than 99%, and the purity of the resulting R-CHBE enantiomer is greater than 99%. This invention reduces dependence on high-purity ECAA raw materials and has good industrial application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biocatalysis and industrial biotechnology, and particularly relates to a carbonyl reductase catalytic system and its application. Background Technology

[0002] Ethyl (R)-4-chloro-3-hydroxybutyrate (R-CHBE) is an important pharmaceutical and fine chemical intermediate, which can be prepared by the asymmetric reduction of ethyl 4-chloroacetoacetate (ECAA) via ketone reductase, alcohol dehydrogenase, or chemical catalysis. Currently, the technology for asymmetric reduction of ECAA using biocatalysts such as ketone reductase and alcohol dehydrogenase is relatively mature. However, the industrial production of ECAA usually generates byproducts such as ethyl acetoacetate, ethyl 2-chloroacetoacetate, and ethyl 2,4-dichloroacetoacetate, which have similar structures and physicochemical properties to ECAA. To obtain high-purity ECAA, separation steps such as distillation are required, resulting in some raw material loss. Currently, the market price of low-purity industrial-grade ECAA is approximately RMB 30,000–40,000 / ton, while the price of high-purity ECAA is approximately RMB 60,000–70,000 / ton. Raw material purification significantly increases production costs. Therefore, directly utilizing low-purity industrial-grade ECAA for catalytic conversion is of great significance for reducing the production cost of R-CHBE.

[0003] On the other hand, non-target components contained in industrial-grade low-purity ECAA may adversely affect the catalytic stability of reductases. Furthermore, at high substrate concentrations above 100 g / L, the combined effects of raw material impurities, substrates, and products on the enzyme catalytic system become more pronounced. Therefore, maintaining high catalytic stability and conversion efficiency of reductases under industrial-grade low-purity ECAA conditions is a key issue that needs to be addressed for the industrial application of ECAA-based R-CHBE preparation. Existing enzyme modification technologies mainly focus on catalytic activity, thermal stability, and stereoselectivity, lacking specific solutions for industrial-grade low-purity ECAA, high substrate concentrations, and the synergistic effects between enzyme catalytic stability and the organic / aqueous two-phase system. Therefore, it remains necessary to develop a biocatalytic system that can be directly applied to industrial-grade low-purity ECAA and maintain stable catalytic performance at higher substrate concentrations, thereby reducing dependence on high-purity ECAA raw materials and improving the industrial applicability of the R-CHBE biomanufacturing process. Summary of the Invention

[0004] The purpose of this invention is to provide a carbonyl reductase catalytic system and its application, aiming to solve the problems mentioned in the background art.

[0005] The present invention is implemented as follows: a carbonyl reductase, which has the activity of catalyzing the asymmetric reduction of ECAA to R-CHBE, and its amino acid sequence is shown in SEQ ID NO.1, and the nucleotide sequence of the gene encoding the reductase is shown in SEQ ID NO.2.

[0006] Further technical solutions involve modifying amino acid sites that affect enzyme catalytic activity and stability through sequence analysis, structure prediction, molecular simulation, rational design, directed evolution, or combinations thereof, to obtain one or more reductase variants. These reductase variants contain one or more amino acid substitutions, deletions, insertions, or additions, while maintaining the asymmetric reduction activity of ECAA.

[0007] In a further technical solution, the reductase variant comprises at least one of mutation point a, mutation point b, and mutation point c:

[0008] Mutation point a: The mutant A11L obtained by mutating alanine at position 11 of the amino acid sequence shown in SEQ ID NO.1 to leucine is named SsAR-A11L;

[0009] Mutation point b: The mutant K257P obtained by mutating lysine at position 257 of the amino acid sequence shown in SEQ ID NO.1 to proline is named SsAR-K257P.

[0010] Mutation point c: The mutant G265E obtained by mutating glycine at position 265 of the amino acid sequence shown in SEQ ID NO.1 to glutamic acid is named SsAR-G265E.

[0011] Another objective of this invention is to provide a recombinant microorganism expressing the aforementioned reductase and its coenzyme regeneration system. The encoding nucleic acid of the reductase is constructed into a recombinant expression vector and introduced into a suitable host cell to obtain a recombinant microorganism expressing the reductase. The host cell is *Escherichia coli*, yeast, or other microorganisms capable of expressing the reductase, preferably *Escherichia coli*. To achieve continuous regeneration of the coenzyme during the catalytic process, the reductase and the coenzyme regeneration enzyme are co-expressed or co-used in the catalytic system. Preferably, the coenzyme regeneration enzyme is glucose dehydrogenase (GDH), using glucose as the coenzyme regeneration substrate, and achieving the cyclic regeneration of NADH or NADPH through glucose oxidation. The coenzyme regeneration enzyme can also be alcohol dehydrogenase, isopropanol dehydrogenase, or other enzymes with corresponding coenzyme regeneration capabilities.

[0012] Another objective of this invention is to provide an organic / aqueous two-phase biocatalytic system suitable for industrial-grade low-purity ECAA. The aqueous phase is a phosphate buffer, Tris buffer, or other buffer system suitable for reductase catalysis. The organic phase is selected from one or more of toluene, butyl acetate, methyl tert-butyl ether (MTBE), and n-hexane. By adjusting the ratio of the organic phase to the aqueous phase, the distribution of non-target components in ECAA, R-CHBE, and industrial-grade ECAA in the two phases is altered, thereby reducing the effective exposure of non-target components in the aqueous phase containing the reductase.

[0013] Preferably, the volume ratio of the organic phase to the aqueous phase is 0.5:1 to 2:1; more preferably, the volume ratio of the organic phase to the aqueous phase is about 1:1.

[0014] Another objective of this invention is to provide a method for high-concentration asymmetric reduction using industrial-grade low-purity ECAA. The method uses industrial-grade ECAA as a substrate and performs asymmetric reduction in the presence of the aforementioned reductase, recombinant microorganisms, or a biocatalytic system to generate R-CHBE. The purity of the industrial-grade ECAA is 90%–99%, preferably about 95%. The concentration of ECAA in the reaction system is 50–150 g / L; preferably 80–130 g / L; more preferably 100–120 g / L. During the reaction, NADH or NADPH is used as a coenzyme, and coenzyme cycling is achieved through GDH, alcohol dehydrogenase, isopropanol dehydrogenase, or other coenzyme regeneration enzymes. Preferably, glucose is used as the coenzyme regeneration substrate, and continuous regeneration of NADH or NADPH is achieved through glucose dehydrogenase.

[0015] Another objective of this invention is to provide the application of the aforementioned reductase, recombinant microorganisms, and biocatalytic system in the preparation of R-CHBE. Preferably, industrial-grade ECAA with a purity of approximately 95% is used as the raw material, and asymmetric reduction is carried out under high substrate concentration conditions of 100–120 g / L. By controlling the reaction temperature, pH, enzyme dosage, coenzyme concentration, coenzyme regeneration substrate concentration, and organic phase / aqueous phase ratio, ECAA maintains a high conversion efficiency. Preferably, under conditions where the reaction time does not exceed 10 h, ECAA achieves essentially quantitative conversion, obtaining R-CHBE with an enantiomeric purity greater than 99%. The reaction product is then subjected to phase separation, extraction, concentration, and necessary purification treatments to obtain the R-CHBE product.

[0016] The carbonyl reductase catalytic system and its application provided in this invention have the following beneficial effects:

[0017] (1) By modifying the stability of ECAA reductase, the reductase can better adapt to the complex raw material environment in industrial-grade low-purity ECAA, and reduce the adverse effects of non-target components on enzyme catalytic performance.

[0018] (2) By combining reductase and coenzyme regeneration enzyme, the coenzyme can be recycled during the catalytic process, reducing the consumption of exogenous coenzyme and improving the continuous reaction capacity of the catalytic system.

[0019] (3) Further adopt an organic / aqueous two-phase catalytic system, and improve the distribution of substrate, product and non-target components in the reaction system by adjusting the ratio of the two phases, thereby improving the enzyme catalytic stability under industrial-grade ECAA conditions.

[0020] (4) It can directly use industrial-grade ECAA with a purity of about 95% as a substrate and perform asymmetric reduction at a high substrate concentration of more than 100 g / L, thereby reducing the dependence on high-purity ECAA raw materials.

[0021] (5) Under preferred conditions, 100-120 g / L industrial grade ECAA is used for the reaction, and the reaction time does not exceed 10 h. ECAA can be quantitatively converted and R-CHBE with enantiomeric purity greater than 99% is obtained.

[0022] (6) Combining the reductase with enhanced stability, the efficient coenzyme regeneration system and the organic / aqueous two-phase system forms an overall solution for high-concentration catalysis of industrial-grade low-purity ECAA, which is conducive to reducing the cost of raw material refining and improving the industrial applicability of the R-CHBE biomanufacturing process. Attached Figure Description

[0023] Figure 1 This is a schematic diagram of an asymmetric reduction of carbonyl reductase and coenzyme regeneration reaction provided in an embodiment of the present invention;

[0024] Figure 2 The protein expression results of a carbonyl reductase and its modified form provided in the embodiments of the present invention;

[0025] Figure 3 The conversion rate of the product prepared by R-CHBE was measured.

[0026] Figure 4 To determine the enantiomeric purity of the product prepared by R-CHBE. Detailed Implementation

[0027] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described in detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are merely illustrative and not intended to limit the invention.

[0028] The specific implementation of the present invention will be described in detail below with reference to specific embodiments.

[0029] One embodiment of the present invention provides a carbonyl reductase, wherein the hydroxyl reductase is an ECAA reductase with high catalytic stability, named SsAR. The reductase SsAR has the activity of catalyzing the asymmetric reduction of ECAA to R-CHBE, and its amino acid sequence is shown in SEQ ID NO.1. The nucleotide sequence of the gene encoding this reductase is shown in SEQ ID NO.2.

[0030] This invention utilizes sequence analysis, structure prediction, molecular simulation, rational design, directed evolution, or a combination thereof to modify amino acid sites affecting enzyme catalytic activity and stability, thereby obtaining one or more reductase variants. These reductase variants contain one or more amino acid substitutions, deletions, insertions, or additions, while maintaining the asymmetric reduction activity of ECAA. Compared to unmodified wild-type reductases, these reductase variants exhibit higher catalytic stability and substrate conversion ability under industrial-grade low-purity ECAA conditions.

[0031] The reductase variant contains at least one of mutation point a, mutation point b, and mutation point c:

[0032] Mutation point a: The mutant A11L obtained by mutating alanine at position 11 of the amino acid sequence shown in SEQ ID NO.1 to leucine is named SsAR-A11L;

[0033] Mutation point b: The mutant K257P obtained by mutating lysine at position 257 of the amino acid sequence shown in SEQ ID NO.1 to proline is named SsAR-K257P.

[0034] Mutation point c: The mutant G265E obtained by mutating glycine at position 265 of the amino acid sequence shown in SEQ ID NO.1 to glutamic acid is named SsAR-G265E.

[0035] Another embodiment of the present invention provides a recombinant microorganism expressing the above-mentioned reductase and its coenzyme regeneration system. The present invention constructs the encoding nucleic acid of the above-mentioned reductase into a recombinant expression vector and introduces it into a suitable host cell to obtain a recombinant microorganism expressing the reductase. The host cell is *Escherichia coli*, yeast, or other microorganisms capable of expressing the reductase, preferably *Escherichia coli*. To achieve continuous regeneration of the coenzyme during the catalytic process, the reductase and the coenzyme regeneration enzyme are co-expressed or co-used in the catalytic system.

[0036] Preferably, the coenzyme regenerating enzyme is glucose dehydrogenase (GDH), which uses glucose as a coenzyme regeneration substrate and achieves the cyclic regeneration of reduced β-nicotinamide adenosine dinucleotide (NADH) or reduced β-nicotinamide adenine dinucleotide phosphate (NADPH) through glucose oxidation. The coenzyme regenerating enzyme can also be alcohol dehydrogenase, isopropanol dehydrogenase, or other enzymes with corresponding coenzyme regeneration capabilities. Figure 1 ).

[0037] Another embodiment of the present invention provides an organic / aqueous two-phase biocatalytic system suitable for industrial-grade low-purity ECAA. The aqueous phase is a phosphate buffer, Tris buffer, or other buffer system suitable for reductase catalysis. The organic phase is selected from one or more of toluene, butyl acetate, methyl tert-butyl ether (MTBE), and n-hexane. By adjusting the ratio of the organic phase to the aqueous phase, the distribution of non-target components in ECAA, R-CHBE, and industrial-grade ECAA in the two phases is changed, thereby reducing the effective exposure of non-target components in the aqueous phase containing the reductase.

[0038] Preferably, the volume ratio of the organic phase to the aqueous phase is 0.5:1 to 2:1; more preferably, the volume ratio of the organic phase to the aqueous phase is about 1:1.

[0039] Another embodiment of the present invention provides a method for high-concentration asymmetric reduction using industrial-grade low-purity ECAA. The method uses industrial-grade ECAA as a substrate and performs asymmetric reduction in the presence of the aforementioned reductase, recombinant microorganisms, or a biocatalytic system to generate R-CHBE. The purity of the industrial-grade ECAA is 90%–99%, preferably about 95%. The concentration of ECAA in the reaction system is 50–150 g / L; preferably 80–130 g / L; more preferably 100–120 g / L. During the reaction, NADH or NADPH is used as a coenzyme, and a coenzyme cycle is achieved through GDH, alcohol dehydrogenase, isopropanol dehydrogenase, or other coenzyme regeneration enzymes.

[0040] Preferably, glucose is used as a coenzyme regeneration substrate, and continuous regeneration of NADH or NADPH is achieved through glucose dehydrogenase.

[0041] Another embodiment of the present invention provides the application of the above-mentioned reductase, recombinant microorganism, and biocatalytic system in the preparation of R-CHBE. Preferably, industrial-grade ECAA with a purity of approximately 95% is used as the raw material, and asymmetric reduction is carried out under high substrate concentration conditions of 100–120 g / L. By controlling the reaction temperature, pH, enzyme addition amount, coenzyme concentration, coenzyme regeneration substrate concentration, and organic phase / aqueous phase ratio, ECAA maintains a high conversion efficiency.

[0042] Preferably, under conditions where the reaction time does not exceed 10 h, ECAA achieves essentially quantitative conversion and obtains R-CHBE with an enantiomeric purity greater than 99%. The reaction product is then subjected to phase separation, extraction, concentration, and necessary purification treatments to obtain the R-CHBE product.

[0043] The following verification is based on several specific embodiments.

[0044] Example 1: Obtaining the reductase SsAR and its mutant enzyme and the GDH gene sequence;

[0045] Using the wild-type reductase SsAR, which exhibits ECAA asymmetric reduction activity, as the parent enzyme, the reductase SsAR catalyzes the asymmetric reduction of ECAA to R-CHBE. Its amino acid sequence is shown in SEQ ID NO. 1, and the nucleotide sequence of the gene encoding this reductase is shown in SEQ ID NO. 2. Based on its amino acid sequence, structural prediction and sequence analysis were performed. Combined with molecular simulation results, amino acid sites that may affect the enzyme's catalytic stability were screened, and corresponding mutant genes were synthesized based on the designed mutation sites. The GDH gene sequence is shown in SEQ ID NO. 3.

[0046] Example 2: Construction of recombinant plasmids;

[0047] The recombinant plasmid pET_32a_SsAR_GDH was constructed by linking the reductase SsAR and its mutant enzyme gene sequences to the GDH gene sequence via RBS, and then inserting them into the pET_32a plasmid vector using BamHI and HindIII restriction endonuclease sites. Primers with RBS sequences and homologous arms are shown in Table 1.

[0048] Table 1 Primers

[0049]

[0050] Example 3: Expression of reductase and its mutant enzyme;

[0051] The recombinant plasmids were transformed into competent *E. coli* cells and plated on LB solid medium containing ampicillin (100 mg / L), incubated at 37 °C for 12–16 h. Single colonies were picked and inoculated into 5 mL of LB liquid medium, incubated at 37 °C and 200 rpm for 8–12 h to obtain activated bacterial culture. The activated bacterial culture was then transferred to secondary seed culture medium at an inoculum rate of 1%–2%, and incubated at 37 °C and 200 rpm until OD500 reached. 600 The inoculum size was 0.6–0.8. Subsequently, 5%–10% of the inoculum was transferred to 5L of fermentation medium for scale-up culture. When the bacterial OD... 600When the concentration reached 20, isopropyl-β-D-thiogalactopyranoside (IPTG) was added to a final concentration of 0.5 mM for induction, and the cells were cultured at 25 °C for another 7 h. After the culture was completed, the cells were collected by centrifugation at 4 °C and 8000–10000 rpm for 10 min. The obtained cells were analyzed by SDS-PAGE to detect the expression of the target reductase. Figure 2 The results showed that protein bands corresponding to the molecular weight of the target reductase appeared in the bacterial cells after induction, indicating that the reductase provided by this invention can be effectively expressed in Escherichia coli.

[0052] Example 4: Evaluation of the catalytic stability of reductase variants;

[0053] (1) Methods for measuring enzyme activity:

[0054] Enzyme activity was determined at 30 °C by measuring the decrease in NAD(P)H absorbance at 340 nm. One unit of enzyme activity was defined as the amount of enzyme that catalyzes the reduction of 1.0 μmol NADP+ or the oxidation of 1.0 μmol NADPH per minute at the optimum temperature. The reaction system consisted of 100 mM phosphate buffer (pH 7.0), 0.2 mM NADPH, 5 mM substrate, and purified enzyme, with a total volume of 300 μL. The reaction without added enzyme served as a control.

[0055] To evaluate the stability of the reductase, the parent reductase and the modified reductase were pretreated at 30, 35, 40, 45, and 50 °C for 8 h, respectively. Residual enzyme activity was then measured under the same reaction conditions, with the activity before pretreatment considered as 100%. The experimental results showed that the modified reductase of this invention had higher residual enzyme activity compared to wild-type SsAR, indicating that the amino acid modification could improve the catalytic stability of the reductase. Enzyme activity, residual enzyme activity, and stability parameters before and after modification are shown in Table 2.

[0056] Table 2 Comparison of catalytic performance and stability of reductase before and after modification

[0057]

[0058] Example 5: Preparation of R-CHBE from high-concentration industrial-grade ECAA;

[0059] Industrial-grade ECAA with a purity of approximately 95% was used as the substrate. 500 mL of phosphate buffer and 500 mL of MTBE were added to a 2000 mL round-bottom flask. Industrial-grade ECAA with a purity of approximately 95% was then added to achieve final concentrations of 100 g / L, 110 g / L, and 120 g / L, respectively. 100 g / L of engineered bacterial cells containing the SsAR-K257P mutant enzyme and 140 g / L of glucose were added to the above reaction system. The reaction system was placed in a 30 °C constant-temperature shaker and stirred at 200–300 rpm. Samples were taken at 0, 2, 4, 6, 8, and 10 h of reaction, and the residual ECAA was detected by gas chromatography and chiral chromatography. Figure 3 ) and R-CHBE production amount and enantiomeric purity ( Figure 4 After the reaction was completed, the mixture was centrifuged at 10,000 rpm for 10 min to allow the organic and aqueous phases to separate completely. The organic phase was collected, concentrated, and further purified to obtain the R-CHBE product. The catalytic results of industrial-grade ECAA at different substrate concentrations are shown in Table 3 below.

[0060] Table 3 Catalytic results of industrial-grade ECAA at different substrate concentrations

[0061]

[0062] The results show that the modified reductase of this invention can maintain high catalytic performance under conditions of industrial-grade ECAA purity of about 95% and high substrate concentration of 100-120 g / L.

[0063] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, and improvements made within the spirit and principles of the present invention should be included within the protection scope of the present invention.

Claims

1. A carbonyl reductase, characterized in that, The carbonyl reductase has the activity of catalyzing the asymmetric reduction of ECAA to R-CHBE, and its amino acid sequence is shown in SEQ ID NO.1, or is a reductase variant obtained by substituting, deleting, inserting or adding one or more amino acids into the amino acid sequence shown in SEQ ID NO.1; The reductase variant contains one or more amino acid substitutions at positions 11, 257, and 265.

2. The carbonyl reductase according to claim 1, characterized in that, The reductase variant contains at least one of mutation point a, mutation point b, and mutation point c: Mutation point a: The mutant A11L obtained by mutating alanine at position 11 of the amino acid sequence shown in SEQ ID NO.1 to leucine is named SsAR-A11L; Mutation point b: The mutant K257P obtained by mutating lysine at position 257 of the amino acid sequence shown in SEQ ID NO.1 to proline is named SsAR-K257P. Mutation point c: The mutant G265E obtained by mutating glycine at position 265 of the amino acid sequence shown in SEQ ID NO.1 to glutamic acid is named SsAR-G265E.

3. A nucleic acid molecule, characterized in that, The nucleic acid molecule encodes the carbonyl reductase as described in any one of claims 1-2.

4. A recombinant expression vector, characterized in that, It includes the nucleic acid molecule as described in claim 3.

5. A recombinant microorganism, characterized in that, The recombinant microorganism expresses the carbonyl reductase as described in claim 1 or 2, and expresses a coenzyme regenerase for NADH or NADPH regeneration.

6. The recombinant microorganism according to claim 5, characterized in that, The coenzyme regenerating enzyme is selected from one or more of glucose dehydrogenase, alcohol dehydrogenase and isopropanol dehydrogenase. The recombinant microorganism is Escherichia coli.

7. A biocatalytic system for the asymmetric reduction of ECAA, characterized in that, Includes the recombinant microorganisms, coenzyme, coenzyme regenerating enzyme, aqueous phase, and organic phase as described in claim 6; The aqueous phase is a buffer solution, and the organic phase is selected from one or more of toluene, butyl acetate, methyl tert-butyl ether, and n-hexane.

8. The biocatalytic system for the asymmetric reduction of ECAA according to claim 7, characterized in that, The volume ratio of the organic phase to the aqueous phase is 0.5:1 to 2:1; The coenzyme is NADH or NADPH, the coenzyme regenerating enzyme is glucose dehydrogenase, and the coenzyme regeneration substrate is glucose.

9. A method for asymmetric reduction of ECAA, characterized in that, Includes the following steps: Industrial-grade ECAA is contacted with the recombinant microorganism described in claim 6, and asymmetric reduction is performed in the presence of coenzyme and coenzyme regeneration system to obtain R-CHBE.

10. The method for asymmetric reduction of ECAA according to claim 9, characterized in that, The purity of the industrial-grade ECAA is 90%–99%; The reaction concentration of ECAA is 50–150 g / L; The reaction system is an organic / aqueous two-phase system, and the volume ratio of the organic phase to the aqueous phase is 0.5:1 to 2:

1. The reaction time should not exceed 10 hours.